Partial Rescue of Biochemical Parameters After Hematopoietic Stem Cell Transplantation in a Patient with Prolidase Deficiency Due to Two Novel PEPD Mutations
- 27 September 2011
- book chapter
- Published by Springer Nature
- Vol. 3, 71-77
Abstract
Prolidase deficiency (PD) is a rare recessive disorder resulting from mutations in the prolidase gene (PEPD); only 17 causative mutant alleles had been so far characterized. Prolidase is a ubiquitous enzyme that hydrolyses dipeptides with C-terminal proline or hydroxyproline residues and indeed, lack of this enzyme activity causes massive urine excretion of undigested iminodipeptides. The clinical manifestations of PD are widely variable, and include intractable skin ulcers, unusual face, different degree of mental retardation, and recurrent infections. No definitive treatment is at present available. We report an 8-year girl with a typical PD facies, normal intelligence, and recurrent deep ulcerations complicated by infections. She was found to be compound heterozygous for two novel mutations in PEPD, c.1133delACG and c.1301delT, affecting the C-terminal end of the enzyme where the active site is located. Given her life-threatening course, she underwent allogeneic hematopoietic stem cell transplantation (HSCT) from her HLA-identical brother, confirmed heterozygous for the c.1133delACG allele. Successful engraftment was documented by full-donor chimerism. Posttransplant monitoring of erythrocyte prolidase activity showed that the child had converted to a heterozygous pattern. Reduction of excreted urine dipeptides, evaluated by capillary electrophoresis, supported the effectiveness of the treatment. Unfortunately the patient died on day +92 of invasive fungal infection. Despite the unfavorable outcome, we provide the first evidence that HSCT has the potential to reverse some of the biochemical features of PD patients. The indication to transplant must be balanced against the clinical manifestation of individual patients.Keywords
This publication has 20 references indexed in Scilit:
- Novel Trafficking Routes for Hematopoietic Stem and Progenitor CellsAnnals of the New York Academy of Sciences, 2009
- New perspectives in human stem cell therapeutic researchBMC Medicine, 2009
- Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor ProgramTransplantation and Cellular Therapy, 2008
- Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutationsAmino Acids, 2008
- Emerging trends in transplantation of inherited metabolic diseasesBone Marrow Transplantation, 2008
- N-benzyloxycarbonyl-l-proline: An in vitro and in vivo inhibitor of prolidaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2005
- Characterization of a new PEPD allele causing prolidase deficiency in two unrelated patients: natural-occurrent mutations as a tool to investigate structure–function relationshipJournal of Human Genetics, 2004
- Mutation analysis of five new patients affected by prolidase deficiency: the lack of enzyme activity causes necrosis-like cell death in cultured fibroblastsHuman Genetics, 2002
- Blood transfusions in the therapy of a case of prolidase deficiencyBritish Journal of Dermatology, 1992
- Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduriaClinica Chimica Acta, 1982